TICKERNERD
Menu
ARTVARTVHealthcare · Biotechnology

ARTV Stock Forecast: Artiva Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$10
−1.92% on the day

The 6 Wall Street analysts covering Artiva Biotherapeutics, Inc. hold a median 12-month price target of $40 — +291.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$499.7M
Ticker Nerd rank
38 / 100
Median analyst target
$40
Analysts covering
6
Revenue$0.0
Operating income−$26.9M
Net income−$25.0M
Free cash flow−$20.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.1%
1M
−13.2%
YTD
+138.2%
1Y
+284.2%
From 52W high
−23.7%
From 52W low
+348.2%
$2
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARTV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Artiva Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
81
Accruals
59
Size
53
Revisions
48
Growth
48
Quality
43
Issuance
35
Value
30
Volatility
5

Momentum (81): The shares have been drifting up relative to others.

Volatility (5): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARTV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARTV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40Oct 25Jan 26Apr 26Jul 26ARTVHigh $41Median $40Low $23

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6 Buy0 Hold0 Sell
Low $23Median $40High $41

The green dot is the last close — the median target sits +291.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 June 2026NeedhamReiteratesBuy$41
12 May 2026NeedhamMaintainsBuy—
11 May 2026Cantor FitzgeraldMaintainsOverweight—
11 May 2026WedbushMaintainsOutperform—
8 May 2026HC Wainwright & Co.MaintainsBuy—
4 May 2026NeedhamReiteratesBuy—
11 Mar 2026NeedhamReiteratesBuy—
12 Nov 2025HC Wainwright & Co.MaintainsBuy—
17 Oct 2025NeedhamReiteratesBuy—
17 Oct 2025WedbushMaintainsOutperform—
11 June 2025HC Wainwright & Co.AssumesBuy$12
15 May 2025NeedhamMaintainsBuy—
8 Apr 2025NeedhamReiteratesBuy—
26 Mar 2025HC Wainwright & Co.ReiteratesBuy—
25 Mar 2025Cantor FitzgeraldMaintainsOverweight—
25 Mar 2025NeedhamReiteratesBuy—
25 Mar 2025WedbushReiteratesOutperform—
30 Dec 2024HC Wainwright & Co.InitiatesBuy—
13 Nov 2024NeedhamReiteratesBuy—
30 Aug 2024NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARTV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ARTV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Artiva Biotherapeutics, Inc. returned +284.2% against +17.5% for the S&P 500, dividends included.

ARTV vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Oct 25Jan 26Apr 26Jul 26ARTVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ARTV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Artiva Biotherapeutics, Inc. (ARTV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.0×

Cheaper than 87% of US stocks

Price / sales
—
Price / book
1.4×

Cheaper than 57% of US stocks

EV / EBITDA
−1.7×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−36.6%

Higher than 25% of US stocks

Return on assets
−22.3%

Higher than 18% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Artiva Biotherapeutics, Inc. (ARTV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Artiva Biotherapeutics, Inc. has a market value of $499.7M and an enterprise value of $160.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$90.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$76.9M.

  • Shares outstanding: 48.9M.

  • Trailing P/E: −3.0×; forward P/E: −3.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Artiva Biotherapeutics, Inc. employs 115 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

ARTV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARTVArtiva Biotherapeutics, Inc.$499.7M
38
ZURAZura Bio Ltd.$494.3M
32
ENTXEntera Bio Ltd.$491.7M
49
IRDOpus Genetics, Inc.$491.6M
58
OVIDOvid Therapeutics, Inc.$502.1M
67
VOGXVogenx, Inc.$485.9M
1
EIKNEikon Therapeutics, Inc.$483.7M
1

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Artiva Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARTV news & analysis

Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026

GlobeNewsWire · 8 Sept 2026positive

Artiva Biotherapeutics provided an update on anticipated AlloNK data disclosures and development milestones through year-end 2026. The company expects updated clinical data in the second half of 2026 for patients with refractory rheumatoid arthritis, Sjögren disease, and systemic sclerosis, and plans to initiate a Phase 3 registrational trial of AlloNK plus rituximab in about 150 refractory RA patients.

Why it matters — ARTV watchers would care because the update outlines near-term data readouts and the initiation of its Phase 3 registrational trial, key milestones for the lead AlloNK program.

Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September

GlobeNewsWire · 2 Sept 2026neutral

Artiva Biotherapeutics announced that its management will participate in upcoming investor conferences in September, including a live fireside chat at the 2026 Cantor Global Healthcare Conference on September 9, 2026. The company is a clinical-stage biotechnology firm developing cell therapies for autoimmune diseases.

Why it matters — An ARTV watcher would care because the company's participation in investor conferences offers opportunities for management to present and potentially generate interest among the investment community.

Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewsWire · 6 Aug 2026positive

Artiva Biotherapeutics reported second quarter 2026 financial results, highlighting translational data presented at EULAR 2026 for AlloNK and an FDA Regenerative Medicine Advanced Therapy designation for AlloNK plus rituximab in refractory rheumatoid arthritis. The company is initiating a Phase 3 registrational trial in approximately 150 refractory RA patients in the second half of 2026, and reported $349.4 million in cash, cash equivalents and investments as of June 30, 2026, expected to fund operations into 2029.

Why it matters — ARTV watchers would care because FDA RMAT designation, the planned Phase 3 trial in refractory RA, and a cash runway into 2029 mark key clinical and regulatory progress for AlloNK.

FAQ

Frequently asked questions about ARTV stock

What is the ARTV stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Artiva Biotherapeutics, Inc. have a median 12-month price target of $40, with estimates ranging from $23 to $41. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARTV stock a buy right now?

Of the 6 analysts covering Artiva Biotherapeutics, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Artiva Biotherapeutics, Inc. 38 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARTV?

As at 12 Sept 2026, Artiva Biotherapeutics, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (81 of 100).

Will ARTV stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +291.4% from the last close, and Ticker Nerd's factor model ranks Artiva Biotherapeutics, Inc. 38 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARTV stock forecast for 2030?

No analyst covering Artiva Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARTV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $41 over the next 12 months.

How has ARTV stock performed over the past year?

Artiva Biotherapeutics, Inc. returned +284.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Artiva Biotherapeutics, Inc. do?

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers.

What is the latest news on ARTV?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026". Artiva Biotherapeutics provided an update on anticipated AlloNK data disclosures and development milestones through year-end 2026. The company expects updated clinical data in the second half of 2026 for patients with refractory rheumatoid arthritis, Sjögren disease, and systemic sclerosis, and plans to initiate a Phase 3 registrational trial of AlloNK plus rituximab in about 150 refractory RA patients.

Company

About Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers. The company’s current portfolio centers on allogeneic, off-the-shelf cell therapies designed to be pre-manufactured, cryopreserved, and delivered ready for use. Its lead program, AlloNK, is being studied in combination with B-cell targeted monoclonal antibodies across multiple autoimmune indications, including lupus nephritis and rheumatoid arthritis, as well as in certain B-cell malignancies. Artiva Biotherapeutics also advances additional NK cell therapy candidates aimed at addressing B-cell driven diseases and hematologic cancers. Based in San Diego, California, Artiva Biotherapeutics plays a specialized role in the cell therapy market by focusing on scalable immunotherapy platforms intended for use in both autoimmune and oncology settings.

CEO Dr. Fred Aslan M.D. · 115 employees · United States · https://www.artivabio.com